tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: AC Immune SA (ACIU), Zymeworks (ZYME) and Thermo Fisher (TMO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AC Immune SA (ACIUResearch Report), Zymeworks (ZYMEResearch Report) and Thermo Fisher (TMOResearch Report) with bullish sentiments.

AC Immune SA (ACIU)

In a report issued on April 28, Marc Goodman from Leerink Partners maintained a Buy rating on AC Immune SA, with a price target of $15.00. The company’s shares closed last Friday at $3.58, close to its 52-week low of $3.34.

According to TipRanks.com, Goodman has 0 stars on 0-5 stars ranking scale with an average return of -2.9% and a 41.6% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc.

Currently, the analyst consensus on AC Immune SA is a Moderate Buy with an average price target of $15.50, which is a 355.9% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.

See the top stocks recommended by analysts >>

Zymeworks (ZYME)

In a report issued on April 28, Andrew Berens from Leerink Partners maintained a Buy rating on Zymeworks. The company’s shares closed last Friday at $6.11, close to its 52-week low of $4.56.

According to TipRanks.com, Berens has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -11.9% and a 37.7% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Deciphera Pharmaceuticals.

Zymeworks has an analyst consensus of Strong Buy, with a price target consensus of $23.20, implying a 222.7% upside from current levels. In a report issued on April 18, Evercore ISI also maintained a Buy rating on the stock with a $15.00 price target.

Thermo Fisher (TMO)

In a report issued on April 28, Puneet Souda from Leerink Partners maintained a Buy rating on Thermo Fisher, with a price target of $700.00. The company’s shares closed last Friday at $552.92.

According to TipRanks.com, Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -11.6% and a 33.2% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

Thermo Fisher has an analyst consensus of Strong Buy, with a price target consensus of $674.22, which is a 20.8% upside from current levels. In a report issued on April 28, Benchmark Co. also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ACIU:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed